Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease

Ann Rheum Dis. 2022 Jan;81(1):e11. doi: 10.1136/annrheumdis-2019-216610. Epub 2019 Dec 9.

Authors

Corrado Campochiaro^#^{1

2}, Giulio Cavalli^#^{3

2}, Nicola Farina^{3

2}, Alessandro Tomelleri^{3

2}, Giacomo De Luca^{3

2}, Lorenzo Dagna^{3

2}

Affiliations

¹ Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy campochiaro.corrado@hsr.it.
² Vita-Salute San Raffaele University, Milan, Italy.
³ Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy.

^# Contributed equally.

PMID: 31818808
DOI: 10.1136/annrheumdis-2019-216610

No abstract available

Keywords: autoimmunity; inflammation; treatment.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Combined Modality Therapy
Erdheim-Chester Disease* / diagnostic imaging
Erdheim-Chester Disease* / drug therapy
Humans
Interleukin 1 Receptor Antagonist Protein
Interleukin-1
Protein Kinase Inhibitors / adverse effects

Substances

Interleukin 1 Receptor Antagonist Protein
Interleukin-1
Protein Kinase Inhibitors